Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
Hello March! To round out February, we take a deep look at the winding history of an Alzheimer’s drug on the brink of approval, US regulators’ latest thinking on accelerated approvals, next steps for some of the biggest names in pharma, and more. Oh, and as of this writing, $XBI is still hovering above $100 — a threshold the index finally crossed this week after a two-year lull.
Eli Lilly’s Alzheimer’s trek
Twenty-nine years ago, Eli Lilly bought the childhood home of German pathologist Alois Alzheimer with plans to celebrate, in that house, approvals for drugs to treat the disease named after…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
